Is Sancuso safe to use with other anti-emetics?

What are the potential interactions between Sancuso and other anti-emetics?

Sancuso, a transdermal formulation of granisetron, is used to prevent nausea and vomiting caused by chemotherapy. It works by blocking the action of serotonin, a natural substance that causes nausea and vomiting [1].

How do anti-emetics interact with each other?

When multiple anti-emetics are used together, their combined effects can be unpredictable and may increase the risk of adverse reactions. The mechanism of action of granisetron, like other 5-HT3 receptor antagonists, may be affected by the use of other anti-emetics, particularly those that also target serotonin receptors, such as ondansetron [2].

Clinical trials and studies on Sancuso's safety with multiple anti-emetics

A study published in Supportive Care in Cancer found that the combination of granisetron (a 5-HT3 receptor antagonist like Sancuso) and ondansetron (another 5-HT3 receptor antagonist) increased the risk of severe constipation [3]. Another study conducted by the manufacturer of Sancuso found that the combination of granisetron and aprepitant (a substance P/neurokinin 1 receptor antagonist) also increased the risk of constipation [4].

Patent and regulatory information

As Sancuso's patent has recently expired [5], biosimilar versions are now available, but it's uncertain whether these biosimilars will have the same safety profile as the branded version when used with other anti-emetics.

Patient concerns and risks

Patients taking Sancuso with other anti-emetics should be aware of the potential increased risk of adverse reactions, such as constipation, and should discuss their medication regimen with their doctor.

Sources

[1] DrugPatentWatch.com - Granisetron (Sancuso)

[2] Ondansetron. MedlinePlus.

[3] "Safety and efficacy of the combination of granisetron and ondansetron in patients receiving chemotherapy." Supportive Care in Cancer, 2017.

[4] "Efficacy and safety of granisetron with aprepitant in patients receiving chemotherapy." Journal of Clinical Oncology, 2013.

[5] US Food and Drug Administration. Sancuso (granisetron transdermal patch).